TCN, an AKT inhibitor, exhibits potent antitumor activity and enhances radiosensitivity in hypoxic esophageal squamous cell carcinoma in vitro and in vivo.
about
TCN, an AKT inhibitor, exhibits potent antitumor activity and enhances radiosensitivity in hypoxic esophageal squamous cell carcinoma in vitro and in vivo.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
TCN, an AKT inhibitor, exhibit ...... arcinoma in vitro and in vivo.
@en
TCN, an AKT inhibitor, exhibit ...... arcinoma in vitro and in vivo.
@nl
type
label
TCN, an AKT inhibitor, exhibit ...... arcinoma in vitro and in vivo.
@en
TCN, an AKT inhibitor, exhibit ...... arcinoma in vitro and in vivo.
@nl
prefLabel
TCN, an AKT inhibitor, exhibit ...... arcinoma in vitro and in vivo.
@en
TCN, an AKT inhibitor, exhibit ...... arcinoma in vitro and in vivo.
@nl
P2093
P2860
P356
P1433
P1476
TCN, an AKT inhibitor, exhibit ...... arcinoma in vitro and in vivo.
@en
P2093
Jun-Xing Huang
Sheng-Bin Dai
Xin-Chen Sun
P2860
P304
P356
10.3892/OL.2016.5515
P577
2016-12-20T00:00:00Z